Giant LEAPS For Mankind: Bayer's Malik On Breaking The Mold In R&D
Executive Summary
As new scientific breakthroughs are shaking the foundations of pharma and biotech R&D, In Vivo sat down with Bayer's Kemal Malik to hear how the German big pharma is responding to the challenges with its ground-breaking LEAPS program.
You may also be interested in...
Bayer Eyes Indications Beyond BlueRock's Initial Focus With $240m-Plus Buyout
Bayer will acquire the 40.8% of BlueRock that it doesn't already own as the firm's largest investor via a $225m series A round in 2016. A clinical trial for BlueRock's Parkinson's disease candidate is expected to begin later this year.
Building Bayer For The Next Decade And Navigating A Patent Cliff
As Bayer prepares for several of its key products to lose patent exclusivity in four to five years’ time, In Vivo caught up with the company’s new head of pharma, Stefan Oelrich, to hear more on his strategy for the future – especially his plans for drug R&D, collaboration and a pipeline built on external innovation.
Bayer Bosses Beg Risk-Averse Europe To Rethink
The German group believes it is going to be at the forefront of development in the cell and gene therapy space but is worried that Europe is failing to recognize the value that the pharma industry and its new technologies can create for society.